Compare VOR & CII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOR | CII |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 979.0M |
| IPO Year | 2021 | 2004 |
| Metric | VOR | CII |
|---|---|---|
| Price | $19.18 | $21.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $39.00 | N/A |
| AVG Volume (30 Days) | ★ 636.5K | 74.7K |
| Earning Date | 10-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.21 | $20.43 |
| 52 Week High | $26.00 | $26.17 |
| Indicator | VOR | CII |
|---|---|---|
| Relative Strength Index (RSI) | 48.50 | 26.21 |
| Support Level | $17.62 | $21.16 |
| Resistance Level | $20.11 | $24.93 |
| Average True Range (ATR) | 1.29 | 0.50 |
| MACD | -0.09 | -0.18 |
| Stochastic Oscillator | 44.48 | 2.84 |
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. It may invest directly in such securities or synthetically through the use of derivatives. It also seeks to achieve its investment objective by employing a writing (selling) call and put options.